Showing 2441-2450 of 10490 results for "".
FDA Approvals, Acne Insights, EPI Gets Cloderm
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-fda-approvals-acne-insights-epi-gets-cloderm/18230/In a flurry of approvals, FDA gives the nod to Almirall's Seysara (sarecycline), Ortho Dermatologics' Bryhali (halobetasol propionate, 0.01%) Lotion, Paratek Pharmaceuticals' Nuzyra (omadacycline), and Regeneron's Libtayo (cemiplimab). Research shows top earners across various fields in the US mayAllergan's Cool Campaign, Obagi Line Launches, Apple Upgrades Health App
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-allergan-s-cool-campaign-obagi-line-launches-apple-upgrades-health-app/18346/There's some misleading information about fat reduction out there, and that's not cool, Allergan says. The company's CoolSculpting device has launched the “Not Cool Vs. Cool” campaign. Data show patients and doctors assess scars differently: Patients tend to focus on scar depth, while physicians focHad Your Fill?
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/had-your-fill/18531/If the US filler market seems robust, you should see what's available outside the US, says Hassan Galadari, MD. He provides a global perspective on fillers with a focus on up-and-coming products, the importance of understanding anatomy, and advances in recognizing and treating complications.Mentors in Dermatology
https://practicaldermatology.com/topics/practice-management/mentors-in-dermatology/18719/Neal Bhatia, MD sat down with one of his mentees, Al Damavandy, MD, to discuss what makes a great mentee-mentor relationship and how both parties can benefit. Dr. Damavandy, now a practicing Mohs Surgeon and Dermatologist, shared tips for how to find the right mentor and what he learned from his menPearls from NYC: Oy Vey!
https://practicaldermatology.com/topics/skin-cancer-photoprotection/pearls-from-nyc-oy-vey-/18752/By Gary Goldenberg, MD and Seemal R. Desai, MDWhat happens if you shave a melanoma? Dr. Goldenberg addresses a common question from the clinic. The good news? The type of biopsy done does not appear to affect long-term survival in melanoma.Getting the Upper Hand on NMSC
https://practicaldermatology.com/topics/skin-cancer-photoprotection/getting-the-upper-hand-on-nmsc/18758/By Seemal R. Desai, MD and Anthony Rossi, MDDecide what type of treatment to use to treat the specific, biopsy-confirmed presentation, says Dr. Rossi. He shares tips to optimize topical treatment outcomes in non-melanoma skin cancer.Where is Dermatology Headed?
https://practicaldermatology.com/topics/psoriasis/where-is-dermatology-headed/18590/Neal Bhatia, MD and Joel Schlessinger, MD sit down as the medical editors of Practical Dermatology® to discuss the future of dermatology in this episode of Derm Insider. They talk about how an increased focus on research in the last few years is leading to new treatments and new understanding aboutHow Do You Manage the Aesthetic Patient?
https://practicaldermatology.com/topics/practice-management/how-do-you-manage-the-aesthetic-patient/18775/Managing the aesthetic patient is all about building relationships explains Joel L. Cohen, MD, founder of AboutSkin Dermatology in Englewood, CO. Dr. Cohen speaks with host Adam Friedman, MD, Associate Professor of Dermatology, Director, Residency Program, and Director, Translational Research at TheAdvances in Devices for Dermatology
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/advances-in-devices-for-dermatology/18815/M. Christine Lee, MD provides an overview of some of the new and emerging laser technologies. She discusses advances in everything from lasers and light-based devices to radiofrequency, ultrasound, and combination devices for a variety of dermatologic issues including facial rejuvenation, vaginal reValeant Business Update; Melanoma Drugs Approved
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-valeant-business-update-melanoma-drugs-approved/18679/In this edition of DermWireTV from the editors of Practical Dermatology® magazine and DermWire.com, we take a look at Valeant's warning of disruption of dermatology business following its break from specialty pharmacy Philidor. Plus, an update on Melanoma Therapeutics, including approvals of Imlygic